Malvern, PA - There is new hope for the thousands of Americans suffering from mesothelioma, an aggressive form of cancer linked to asbestos exposure. Results from a recent study conducted by researchers at New York University (NYU) School of Medicine show the MESOMARK Assay, the world�s first and only in vitro test for monitoring mesothelioma developed by Fujirebio Diagnostics, Inc., is an effective way to measure proteins within the blood that reflect changes in disease. The findings represent a major milestone in the management of mesothelioma, as the test may enable doctors to more accurately monitor patients for treatment.
read>>>complete press release
